Drug Detail

Information about Votrient + Zolinza

Generic Name
Pazopanib + vorinostat
IND
Brand Name (US)
Votrient + Zolinza
Manufacturer
GlaxoSmithKline & Merck
Drug Type
Tyrosine Kinase Inhibitor + HDAC inhibitor
Delivery
Oral
Approval Status
Both are approved for non-GIST applications
Indications
Kidney cancer, CTCL
Overall Strategy
KIT Protein + GIST cell based
Strategy
Block KIT + Destroy KIT
Drug Category
KIT/PDGFRA inhibitor + HDAC inhibitor

Pazopanib is a potent VEGFR inhibitor but it also inhibits KIT and PDGFRs. It is entering a phase II trial for GIST (~spring 2011).
Vorinostat is a HDAC inhibitor. This class of drugs have multiple modes of activity including inhibition of HSP90 which may result in destruction of the KIT protein.


Links


Trials of this drug

  

Phase I Study of Pazopanib and Vorinostat
   

Trial results


Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed